- Home
- GANX
GANX
Gain Therapeutics Inc.
as 03-28-2025 4:00pm EST
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | BETHESDA |
| Market Cap: | N/A | IPO Year: | 2021 |
| Target Price: | $8.33 | AVG Volume (30 days): | 253.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.89 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.89 - $4.04 | Next Earning Date: | 03-27-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Gain Therapeutics Inc. News
GANX Breaking Stock News: Dive into GANX Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Gain Therapeutics Announces Poster Presentation at AD/PD 2025
GlobeNewswire
2 days ago
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update
MT Newswires
15 days ago
Gain Therapeutics Begins Dosing Parkinson's Patients in GT-02287 Study
ACCESS Newswire
15 days ago
Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease
GlobeNewswire
15 days ago
Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s Disease
GlobeNewswire
23 days ago
Gain Therapeutics Announces Oral Presentation at AD/PD 2025
GlobeNewswire
2 months ago
Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update
GlobeNewswire
2 months ago
Gain Therapeutics To Participate in Upcoming Investor Conferences
Compare GANX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GANX Gain Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.